The Board of Pharmacy, in partnership with the Kansas Hospital Association and Kansas Council of Health-System Pharmacy, developed new naloxone resources to clarify requirements for pharmacy licensees. The guidance distinguishes prescription naloxone dispensed under the Board’s statewide protocol from over-the-counter 4 mg naloxone nasal spray, which may be distributed without following the statewide protocol. The resources are intended to reduce confusion and support broader, appropriate access to this lifesaving opioid-overdose reversal medication.

Also in Kansas, the Board of Pharmacy requires every registered pharmacist, technician and intern to notify the Board within 30 days of starting or ending employment.

For more information, contact NACDS’ Mary Staples at 817-442-1155.